Teleman Dan Benjamin 4

What Happened
Teleman Dan Benjamin, CEO of Nasus Pharma Ltd (NSRX), acquired 6,550 ordinary shares on 2026-06-17 at $3.10 per share, for a total reported cost of $20,305. The transaction is recorded as a purchase (code P), described as an open market or private purchase.

Key Details

• Transaction date and price: 2026-06-17 — 6,550 shares at $3.10 each (total $20,305).
• Filing date: Form 4 filed 2026-06-22 for the 2026-06-17 transaction — this appears to be a late filing (filed more than two business days after the transaction).
• Shares owned after transaction (per footnote): 30,696 ordinary shares, plus 132,845 ordinary shares issuable upon exercise of outstanding options exercisable within 60 days.
• Transaction code: P = Purchase (open market or private purchase).

Context
Purchases by executives can attract attention because they represent direct capital commitment by insiders, though they don’t prove future performance. The filing does not indicate option exercises or sales tied to this purchase; the footnote simply reports current beneficial ownership including exercisable options. The late filing means the market received the disclosure later than SEC timing rules require.